A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Clinical trial NCT02155322 · COMPLETED
Trial details
- NCT number
- NCT02155322
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-19
- Primary completion
- 2016-03-21
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.